List of Chapters/Sections(Table Of Content)
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Drug Type
1.2.1 Global Genetic Obesity Drug Market Size Growth Rate by Drug Type: 2017 VS 2021 VS 2028
1.2.2 Sibutramine
1.2.3 Orlistat
1.2.4 Sympathomimetic Drugs
1.2.5 Receptors Antagonists
1.2.6 Others
1.3 Market by Application
1.3.1 Global Genetic Obesity Drug Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospitals Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Genetic Obesity Drug Market Perspective (2017-2028)
2.2 Genetic Obesity Drug Growth Trends by Region
2.2.1 Genetic Obesity Drug Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Genetic Obesity Drug Historic Market Size by Region (2017-2022)
2.2.3 Genetic Obesity Drug Forecasted Market Size by Region (2023-2028)
2.3 Genetic Obesity Drug Market Dynamics
2.3.1 Genetic Obesity Drug Industry Trends
2.3.2 Genetic Obesity Drug Market Drivers
2.3.3 Genetic Obesity Drug Market Challenges
2.3.4 Genetic Obesity Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Genetic Obesity Drug Players by Revenue
3.1.1 Global Top Genetic Obesity Drug Players by Revenue (2017-2022)
3.1.2 Global Genetic Obesity Drug Revenue Market Share by Players (2017-2022)
3.2 Global Genetic Obesity Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Genetic Obesity Drug Revenue
3.4 Global Genetic Obesity Drug Market Concentration Ratio
3.4.1 Global Genetic Obesity Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Genetic Obesity Drug Revenue in 2021
3.5 Genetic Obesity Drug Key Players Head office and Area Served
3.6 Key Players Genetic Obesity Drug Product Solution and Service
3.7 Date of Enter into Genetic Obesity Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Genetic Obesity Drug Breakdown Data by Drug Type
4.1 Global Genetic Obesity Drug Historic Market Size by Drug Type (2017-2022)
4.2 Global Genetic Obesity Drug Forecasted Market Size by Drug Type (2023-2028)
5 Genetic Obesity Drug Breakdown Data by Application
5.1 Global Genetic Obesity Drug Historic Market Size by Application (2017-2022)
5.2 Global Genetic Obesity Drug Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Genetic Obesity Drug Market Size (2017-2028)
6.2 North America Genetic Obesity Drug Market Size by Country (2017-2022)
6.3 North America Genetic Obesity Drug Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Genetic Obesity Drug Market Size (2017-2028)
7.2 Europe Genetic Obesity Drug Market Size by Country (2017-2022)
7.3 Europe Genetic Obesity Drug Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Genetic Obesity Drug Market Size (2017-2028)
8.2 Asia-Pacific Genetic Obesity Drug Market Size by Country (2017-2022)
8.3 Asia-Pacific Genetic Obesity Drug Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Genetic Obesity Drug Market Size (2017-2028)
9.2 Latin America Genetic Obesity Drug Market Size by Country (2017-2022)
9.3 Latin America Genetic Obesity Drug Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Genetic Obesity Drug Market Size (2017-2028)
10.2 Middle East & Africa Genetic Obesity Drug Market Size by Country (2017-2022)
10.3 Middle East & Africa Genetic Obesity Drug Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Pfizer, Inc.
11.1.1 Pfizer, Inc. Company Detail
11.1.2 Pfizer, Inc. Business Overview
11.1.3 Pfizer, Inc. Genetic Obesity Drug Introduction
11.1.4 Pfizer, Inc. Revenue in Genetic Obesity Drug Business (2017-2022)
11.1.5 Pfizer, Inc. Recent Development
11.2 Sanofi.
11.2.1 Sanofi. Company Detail
11.2.2 Sanofi. Business Overview
11.2.3 Sanofi. Genetic Obesity Drug Introduction
11.2.4 Sanofi. Revenue in Genetic Obesity Drug Business (2017-2022)
11.2.5 Sanofi. Recent Development
11.3 Tonghua Dongbao Pharmaceutical Co., Ltd.
11.3.1 Tonghua Dongbao Pharmaceutical Co., Ltd. Company Detail
11.3.2 Tonghua Dongbao Pharmaceutical Co., Ltd. Business Overview
11.3.3 Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Introduction
11.3.4 Tonghua Dongbao Pharmaceutical Co., Ltd. Revenue in Genetic Obesity Drug Business (2017-2022)
11.3.5 Tonghua Dongbao Pharmaceutical Co., Ltd. Recent Development
11.4 Biocon.
11.4.1 Biocon. Company Detail
11.4.2 Biocon. Business Overview
11.4.3 Biocon. Genetic Obesity Drug Introduction
11.4.4 Biocon. Revenue in Genetic Obesity Drug Business (2017-2022)
11.4.5 Biocon. Recent Development
11.5 Adocia
11.5.1 Adocia Company Detail
11.5.2 Adocia Business Overview
11.5.3 Adocia Genetic Obesity Drug Introduction
11.5.4 Adocia Revenue in Genetic Obesity Drug Business (2017-2022)
11.5.5 Adocia Recent Development
11.6 GlaxoSmithKline Plc.
11.6.1 GlaxoSmithKline Plc. Company Detail
11.6.2 GlaxoSmithKline Plc. Business Overview
11.6.3 GlaxoSmithKline Plc. Genetic Obesity Drug Introduction
11.6.4 GlaxoSmithKline Plc. Revenue in Genetic Obesity Drug Business (2017-2022)
11.6.5 GlaxoSmithKline Plc. Recent Development
11.7 Novo Nordisk A/S.
11.7.1 Novo Nordisk A/S. Company Detail
11.7.2 Novo Nordisk A/S. Business Overview
11.7.3 Novo Nordisk A/S. Genetic Obesity Drug Introduction
11.7.4 Novo Nordisk A/S. Revenue in Genetic Obesity Drug Business (2017-2022)
11.7.5 Novo Nordisk A/S. Recent Development
11.8 Oramed Pharmaceuticals, Inc
11.8.1 Oramed Pharmaceuticals, Inc Company Detail
11.8.2 Oramed Pharmaceuticals, Inc Business Overview
11.8.3 Oramed Pharmaceuticals, Inc Genetic Obesity Drug Introduction
11.8.4 Oramed Pharmaceuticals, Inc Revenue in Genetic Obesity Drug Business (2017-2022)
11.8.5 Oramed Pharmaceuticals, Inc Recent Development
11.9 Wockhardt.
11.9.1 Wockhardt. Company Detail
11.9.2 Wockhardt. Business Overview
11.9.3 Wockhardt. Genetic Obesity Drug Introduction
11.9.4 Wockhardt. Revenue in Genetic Obesity Drug Business (2017-2022)
11.9.5 Wockhardt. Recent Development
11.10 Eli Lilly and Company.
11.10.1 Eli Lilly and Company. Company Detail
11.10.2 Eli Lilly and Company. Business Overview
11.10.3 Eli Lilly and Company. Genetic Obesity Drug Introduction
11.10.4 Eli Lilly and Company. Revenue in Genetic Obesity Drug Business (2017-2022)
11.10.5 Eli Lilly and Company. Recent Development
11.11 Merck & Co., Inc.
11.11.1 Merck & Co., Inc. Company Detail
11.11.2 Merck & Co., Inc. Business Overview
11.11.3 Merck & Co., Inc. Genetic Obesity Drug Introduction
11.11.4 Merck & Co., Inc. Revenue in Genetic Obesity Drug Business (2017-2022)
11.11.5 Merck & Co., Inc. Recent Development
11.12 Julphar.
11.12.1 Julphar. Company Detail
11.12.2 Julphar. Business Overview
11.12.3 Julphar. Genetic Obesity Drug Introduction
11.12.4 Julphar. Revenue in Genetic Obesity Drug Business (2017-2022)
11.12.5 Julphar. Recent Development
11.13 Bristol-Myers Squibb Company.
11.13.1 Bristol-Myers Squibb Company. Company Detail
11.13.2 Bristol-Myers Squibb Company. Business Overview
11.13.3 Bristol-Myers Squibb Company. Genetic Obesity Drug Introduction
11.13.4 Bristol-Myers Squibb Company. Revenue in Genetic Obesity Drug Business (2017-2022)
11.13.5 Bristol-Myers Squibb Company. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
